MX2017004322A - Composicion farmaceutica que comprende aspirina, metformina y serotonina con agente tensioactivo no ionico. - Google Patents

Composicion farmaceutica que comprende aspirina, metformina y serotonina con agente tensioactivo no ionico.

Info

Publication number
MX2017004322A
MX2017004322A MX2017004322A MX2017004322A MX2017004322A MX 2017004322 A MX2017004322 A MX 2017004322A MX 2017004322 A MX2017004322 A MX 2017004322A MX 2017004322 A MX2017004322 A MX 2017004322A MX 2017004322 A MX2017004322 A MX 2017004322A
Authority
MX
Mexico
Prior art keywords
aspirin
metformin
agent
therapeutically effective
pharmaceutical composition
Prior art date
Application number
MX2017004322A
Other languages
English (en)
Inventor
Chen Chien-Hung
Original Assignee
Als Mountain Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Als Mountain Llc filed Critical Als Mountain Llc
Publication of MX2017004322A publication Critical patent/MX2017004322A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se basa sobre el descubrimiento inesperado que una combinacion de determinados farmacos conocidos presenta efectos sinergisticos para tratar el sindrome metabolico y diversas otras enfermedades. En particular, la invencion comprende una composicion farmaceutica que consiste de: (1) una cantidad terapeuticamente efectiva de un primer agente que es metformina o una sal de la misma; (2) una cantidad terapeuticamente efectiva de un segundo agente que es aspirina; (3) una cantidad terapeuticamente efectiva de un tercer agente que es un complejo serotonina creatinina sulfato; (4) un agente tensioactivo no ionico; y (5) un disolvente que es un alcanol inferior. Una composicion preferida comprende clorhidrato de metformina, aspirina y complejo serotonina creatinina sulfato para el primer, segundo y tercer agente. La invencion comprende ademas procedimientos para el uso de estas composiciones para el tratamiento de sindrome metabolico, enfermedades hiperproliferativas incluyendo cancer, y otras enfermedades y condiciones.
MX2017004322A 2014-10-01 2015-10-01 Composicion farmaceutica que comprende aspirina, metformina y serotonina con agente tensioactivo no ionico. MX2017004322A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462058150P 2014-10-01 2014-10-01
PCT/US2015/053475 WO2016054365A1 (en) 2014-10-01 2015-10-01 Pharmaceutical composition comprising aspirin, metformin, and serotonin with non-ionic surfactant

Publications (1)

Publication Number Publication Date
MX2017004322A true MX2017004322A (es) 2017-08-28

Family

ID=55631511

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004322A MX2017004322A (es) 2014-10-01 2015-10-01 Composicion farmaceutica que comprende aspirina, metformina y serotonina con agente tensioactivo no ionico.

Country Status (14)

Country Link
US (1) US20180228818A1 (es)
EP (1) EP3200799A4 (es)
JP (1) JP2017531035A (es)
KR (1) KR20170057451A (es)
CN (1) CN106999496A (es)
AR (1) AR102147A1 (es)
AU (1) AU2015328044A1 (es)
BR (1) BR112017006778A2 (es)
CA (1) CA2961660A1 (es)
MX (1) MX2017004322A (es)
RU (1) RU2017114350A (es)
TW (1) TW201625232A (es)
WO (1) WO2016054365A1 (es)
ZA (1) ZA201702137B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110840869A (zh) * 2019-10-15 2020-02-28 四川大学华西第二医院 二甲双胍在子宫内膜异位症药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CN1984673A (zh) * 2004-05-17 2007-06-20 阿雷斯贸易股份有限公司 干扰素水凝胶制剂
CN101677822A (zh) * 2006-12-11 2010-03-24 普拉罗美德公司 灌注器官止血法
WO2008089212A1 (en) * 2007-01-16 2008-07-24 Ipintl, Llc Novel composition for treating metabolic syndrome
KR20190026056A (ko) * 2008-04-21 2019-03-12 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
PL3111926T3 (pl) * 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje, sposoby i układy do dostarczania dwóch lub większej liczby środków czynnych do układu oddechowego
EA023396B1 (ru) * 2010-04-01 2016-05-31 Фарманест Аб Термогелеобразующие композиции анестетиков
KR20140024292A (ko) * 2011-04-01 2014-02-28 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 치료제의 국소 전달용 감열성, 점막부착성 또는 표피부착성, 및 침투강화성 제제

Also Published As

Publication number Publication date
ZA201702137B (en) 2018-05-30
CN106999496A (zh) 2017-08-01
BR112017006778A2 (pt) 2018-01-09
EP3200799A1 (en) 2017-08-09
WO2016054365A1 (en) 2016-04-07
WO2016054365A8 (en) 2017-04-13
JP2017531035A (ja) 2017-10-19
AU2015328044A8 (en) 2017-04-27
AR102147A1 (es) 2017-02-08
US20180228818A1 (en) 2018-08-16
TW201625232A (zh) 2016-07-16
EP3200799A4 (en) 2018-05-30
RU2017114350A3 (es) 2019-04-22
AU2015328044A1 (en) 2017-04-20
KR20170057451A (ko) 2017-05-24
CA2961660A1 (en) 2016-04-07
RU2017114350A (ru) 2018-11-05

Similar Documents

Publication Publication Date Title
WO2014144130A3 (en) Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof
TW201613887A (en) Antiproliferative compounds and methods of use thereof
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
BR112016024020A8 (pt) composição farmacêutica
WO2016168553A8 (en) Deuterated obeticholic acid
MX2019001850A (es) Formulaciones para administracion oral de principios activos.
MX2016014696A (es) Combinaciones de formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
TN2015000356A1 (en) Bicyclic compounds
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112017014914A2 (pt) terapia combinada para hipertensão pulmonar
PH12018500817A1 (en) Pharmaceutical composition comprising metformin and lobeglitazone
BR112018073556A2 (pt) medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato .
MX2017004322A (es) Composicion farmaceutica que comprende aspirina, metformina y serotonina con agente tensioactivo no ionico.
MX2018003890A (es) Composiciones farmaceuticas que contienen un relajante muscular y un antiinflamatorio no esteroideo (aine).
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.